Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

[Prøving av enhet som ikke er godkjent eller ryddet av U.S. FDA]

10. november 2026 oppdatert av: BioPoly LLC

The goal of this randomized controlled clinical trial is to demonstrate the safety and effectiveness of the BioPoly® Partial Resurfacing Knee Implant for the treatment of cartilage defects of the distal femur in adult patients with knee pain and symptoms who are candidates for surgical intervention of the knee compared to outcomes for the control group.

The primary effectiveness endpoint is Month 24 composite clinical success (CCS) defined by:

  • no secondary surgical intervention (SSI) and
  • an improvement from baseline in the Knee injury and Osteoarthritis Outcome Score (KOOS) total score (scaled 0 to 100) of at least 10 points.

Researchers will compare the CCS for the investigational device group to a control group receiving the standard of care, either microfracture or debridement).

Subjects randomized to the investigational group will receive the BioPoly Knee device and those randomized to the control group will receive the current standard of care, either microfracture or debridement.

Studieoversikt

Detaljert beskrivelse

The BioPoly® Partial Resurfacing Knee Implant is a surgical intervention when conservative therapies have been ineffective for focal cartilage lesions in the femoral condyles and is an early intervention prior to partial or total joint replacement. It is indicated for focal lesions with healthy surrounding and opposing cartilage. Specifically, the BioPoly® device is intended for the replacement of symptomatic abnormal or severely abnormal (ICRS Grade 2, 3 or 4) chondral or osteochondral focal lesions located in the femoral condyles or trochlear facets in patients between 30 and 65 years of age.

The RCT compares the primary endpoint, Composite Clinical Success criteria, for the investigational device, the BioPoly device, to that of the control group, which is the standard of care for these focal lesions either microfracture or debridement.

For those patients who meet eligibility criteria, randomization is 1:1. For the control group, there is a treatment algorithm to determine if microfracture or debridement that is based upon age of the subject, Kellgren-Lawrence score, and lesion size.

Studietype

Intervensjonell

Registrering (Antatt)

152

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • California
      • Redwood City, California, Forente stater, 94063
        • Rekruttering
        • Stanford Medicine Dept of Orthopaedic Surgery
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Seth L Sherman, MD
    • Indiana
      • Fort Wayne, Indiana, Forente stater, 46845
        • Rekruttering
        • Dupont Hospital
        • Hovedetterforsker:
          • Ian Nelson, MD
      • Indianapolis, Indiana, Forente stater, 46278
        • Tilbaketrukket
        • OrthoIndy
    • Kentucky
      • Louisville, Kentucky, Forente stater, 40202
        • Rekruttering
        • University of Louisville
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jarod Richards, M.D.
        • Underetterforsker:
          • David Caborn, M.D.
        • Underetterforsker:
          • Stephanie Boden, M.D.
    • Minnesota
      • Rochester, Minnesota, Forente stater, 55905
        • Rekruttering
        • Mayo Clinic
        • Hovedetterforsker:
          • Daniel Saris, MD
        • Ta kontakt med:
    • Missouri
      • Chesterfield, Missouri, Forente stater, 63017-5701
        • Rekruttering
        • Washington University Orthopedics
        • Ta kontakt med:
        • Hovedetterforsker:
          • Matthew Matava, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

30 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Patient is between 30 and 65 years of age25.
  2. KOOS quality of life score ≤ 60.
  3. In the opinion of the Investigator, the patient has the understanding and willingness to comply with all study requirements including the Post-Operative rehabilitation and follow-up protocol.
  4. Patient has cartilage lesion that has failed non-surgical conservative therapy (e,g, anti-inflammatory (NSAID), viscosupplementation, steroid injection, physical therapy, or activity modification) after at least 2 months of beginning the therapy or failed surgical conservative therapy (e.g. debridement/lavage, marrow stimulation, or alignment high tibial osteotomy) that was performed at least 12 months ago in the index knee and is a candidate for surgical intervention.
  5. Patient has cartilage lesion located in the femoral condyle or trochlear facet.
  6. Patient has lesion(s) classified as ICRS grade 2, 3 or 4.
  7. Patient's lesion size may not exceed 3.1 cm2 and must be circumscribed by a 1.5 cm or 2.0 cm diameter circle, or 1.5 cm (M-L) by 2.4 cm (A-P) oval of normal or nearly normal (ICRS grade 0 or 1) cartilage, with an overall depth less than 4mm from the articulating surface.
  8. Patient has subchondral bone quality that is non-osteoporotic and is sufficient to support the implant. The quality of bone will be assessed by the surgeon intraoperatively with a surgical instrument such as an awl.

Exclusion Criteria:

  1. Patient has body mass index (BMI) ≥ 35.

  2. Patient has autoimmune arthritis, as diagnosed by Investigator.

  3. Patient has advanced degenerative osteoarthritis in index knee (Kellgren-Lawrence Grade 4 and/or diagnosed intraoperatively).

  4. Contralateral knee is known to have symptomatic cartilage, meniscal, or ligamentous lesions, generalized osteoarthritis, or requires surgery.

  5. Patient has gout, by Investigator diagnosis or patient-reported history within last 12 months.

  6. Patient has a cartilage lesion that is being treated with a non-surgical conservative therapy (e,g, anti-inflammatory (NSAID), viscosupplementation, steroid injection, physical therapy, or activity modification) and it has been < 2 months since beginning treatment or the patient's cartilage lesion has failed surgical therapy (e.g. debridement/lavage, marrow stimulation, alignment (high tibial osteotomy)) in the index knee and it has been < 12 months since the surgical treatment.

  7. Patient has a cartilage lesion that is being treated that has failed ACI, OATS or Allograft treatment.

  8. Patient has malalignment of the index knee (>5 degrees weight bearing varus or valgus).

  9. Patient has bipolar articular cartilage involvement (or kissing lesions) of the ipsilateral compartment (i.e. greater than ICRS Grade 2 on the opposing articular surface) in the index knee.

  10. Patient has uncorrected ligamentous instability (good joint stability in the index joint with a Grade 1 Lachman or less, no pivot shift for ACL insufficiency and no posterior translation of more than grade 1; no deficits in flexion or extension of > 10 degrees compared to contralateral knee) in the index knee.

  11. Patient has undergone a total meniscectomy of index knee.

  12. Patient has undergone patellofemoral arthroplasty of the index knee

  13. Patient currently reports or has a documented history of uncontrolled diabetes.

  14. Patient currently has any condition, therapy, or medication known to impair bone healing.

  15. Patient has had an active systemic infection or joint infection in index knee over the last 12 months.

  16. Patient has an allergy to titanium alloy (Ti-6Al-4V), ultrahigh molecular weight polyethylene (UHMWPE), or hyaluronan/ hyaluronic acid (HA).

  17. Patient is pregnant or is planning to become pregnant (for female patients only) at any point during the duration of the study.

  18. Patient has legal involvement or any other issue that would hinder completion of the two-year follow-up period.

  19. Patient is participating in other studies and/or receiving any other simultaneous therapy in index knee.

  20. Patient has an uncorrected tear of the meniscus of the index knee. (Partial meniscectomy that retains >50% of the meniscus is allowed prior to or concurrently with the cartilage treatment procedure. Meniscus suture repair is allowed prior to or concurrently with the cartilage treatment procedure if >50% of the functional meniscus remains.).

  21. Patient has an additional cartilage lesion(s) (ICRS Grade 3 or 4) in the index knee, located on the patella, trochlea, tibia, or non-weight bearing area of index condyle that requires treatment.

  22. More than one implant is required to accommodate defect in the index knee.

  23. Patient has inadequate bone stock (e.g., cysts, osteoporosis) underlying the lesion site as determined intra-operatively by the investigator

    1. As determined by the investigator through use of an awl or a similar instrument to determine if the bone quality is insufficient to support the BioPoly device.
    2. If the cause of inadequate bone stock is due to cysts or to the boney portion of an osteochondral lesion being excessive, then the investigator may opt to fix the implant with cement rather than exclude the patient for inadequate bone stock.
  24. Patients with osteoporosis, osteopenia, Paget's disease, osteomalacia or any other metabolic bone disease; a. Osteoporosis is defined as Simple Calculated Osteoporosis Risk Estimation (SCORE) above 6 and DXA T-score < -2.5 or QCT T-score < 80mg/cubic cm. History of a fragility fracture requires that a DXA scan or QCT scan is completed

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Investigational

BioPoly Knee device

partial resurfacing knee replacement

Aktiv komparator: Control

Surgical Standard of Care Group: either Microfracture or debridement procedure

either microfracture or debridement

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Improvement in the Knee injury and Osteoarthritis Outcome Score (KOOS) to Assess Composite Clinical Success (CCS) effectiveness
Tidsramme: 24 months

An improvement from baseline in the Knee injury and Osteoarthritis Outcome Score (KOOS) total score (scaled 0 to 100) of at least 10 points. If this criteria is met, the subject will be considered as a success relative to the measure of the Clinical Composite Success for effectiveness.

24 months
Composite Clinical Success (CCS) Safety as Measured by No Secondary Surgical Intenvention
Tidsramme: 24 months

No secondary surgical intervention (SSI) by 24 months will be considered as a success for the subject relative to the Composite Clinical Success (CCS) for Safety.

24 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Effectiveness over 24 months as measured by the Knee injury and Osteoarthritis Outcome Score (KOOS)
Tidsramme: 24 months

KOOS individual component sub-scales (Pain, Symptoms, Activities of Daily Living, Sports/Recreation, Quality of Life) as measured by change from baseline at 6 weeks, 3, 6, 12, and 24 months. The minimum and maximum raw scores for each sub-scale is as follows: Pain = 0-36, Symptoms = 0-28, Activities of Daily Living = 0-38, Sports/Recreation = 20, Quality of Life = 0-16. The sub-scales will be reported on a normalized scale relative the maximum raw score for the particular sub-scale, thus, each sub-scale score will have a range of 0-100 with 100 being better. For instance, a subject's Quality of Life raw score of 12 would be normalized as 12/16 x 100 = 75 points. The reported number will be the difference between the normalized score at a particular timepoint minus the baseline normalized score.

24 months
Effectiveness pain reduction over 24 months
Tidsramme: 24 months

Variable Analog Scale (VAS) Pain score as measured by change from baseline at 6 weeks, 3, 6, 12, and 24 months. The VAS Pain score ranges from 0-100 where a lower number is a measure of less pain; so, lower VAS Pain scores are better.

24 months
Adverse Events Over 24 Months
Tidsramme: 24 months
  • Serious device-related adverse events through 24 months
  • Device-related adverse events through 24 months
  • Serious adverse events through 24 months
  • Unanticipated adverse device effects (UADE) through 24 months
24 months
Radiograph review to Assess Implant Stability Over 24 Months
Tidsramme: 24 months

Implant stability over time is assessed by monitoring implant migration/subsidence, implant loosening, and radiolucencies around the implant at 24 months.

24 months
Survival Over 24 Months
Tidsramme: 24 months

A survival analysis will be performed to determine the number of treated and control subjects that did not have a secondary surgical intervention to remove the implant or to perform another procedure to treat the same cartilage lesion.

24 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Herb Schwartz, Ph.D., BioPoly LLC

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. mars 2025

Primær fullføring (Antatt)

1. desember 2028

Studiet fullført (Antatt)

1. desember 2028

Datoer for studieregistrering

Først innsendt

24. mars 2025

Først innsendt som oppfylte QC-kriteriene

3. april 2025

Først lagt ut (Faktiske)

8. april 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Sharing of any data will only be in the aggregate.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere